Cure My Disease

Don't miss your cure!

 Log in / Sign up

Stem cell byproduct may boost ACL graft healing — trial puts it to the test

NCT ID NCT07723625

Disease control Sponsor: PT. Prodia Stem Cell Indonesia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This trial tests whether adding a single injection of MSC-derived secretome — a substance produced by stem cells — during ACL reconstruction surgery can improve knee function and recovery. Twenty-four adults with a complete ACL tear will receive either the secretome or a placebo, and their knee function will be measured before surgery and six months later using standard knee scores. The goal is to see if the secretome helps the graft heal better and leads to a faster, more complete recovery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a single injection of mesenchymal stem cell (MSC)-derived secretome given during ACL reconstruction surgery
What this could lead to
If it works, this could point toward a way to speed up graft healing and improve knee function after ACL surgery.
What could go wrong
This is a small, early-stage trial with only 24 participants, so results may not apply broadly. The secretome is experimental, and its long-term safety and effectiveness are not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

24 people

The number who actually took part.

Started

Nov 2025

Finished

Jul 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 40 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Complete anterior cruciate ligament (ACL) rupture confirmed by magnetic resonance imaging (MRI). * Positive pivot-shift test. * Positive Lachman test. * Positive anterior drawer test. * Scheduled to undergo arthroscopic ACL reconstruction using a peroneus longus tendon autograft. * Surgery performed by the same surgical team. * Age 18 to \<40 years. Exclusion Criteria: * Partial ACL tear. * History of previous ACL reconstruction surgery. * Multi-ligament knee injury involving more than two ligaments. * Generalized ligamentous laxity confirmed using the Beighton Hypermobility Score. * Unwilling or unable to comply with the scheduled follow-up through 6 months postoperatively.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acl injury are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Anterior Cruciate Ligament Injuries

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acl injury Acl tear

Contacts and locations

Locations

  • Prof. dr. I.G.N.G. Ngoerah General Hospital

    Denpasar, Bali, 80113, Indonesia

More trials for these conditions

Other studies related to the condition(s) this trial covers.